MX2009007320A - Anticuerpos neutralizantes del citomegalovirus humano y su uso. - Google Patents

Anticuerpos neutralizantes del citomegalovirus humano y su uso.

Info

Publication number
MX2009007320A
MX2009007320A MX2009007320A MX2009007320A MX2009007320A MX 2009007320 A MX2009007320 A MX 2009007320A MX 2009007320 A MX2009007320 A MX 2009007320A MX 2009007320 A MX2009007320 A MX 2009007320A MX 2009007320 A MX2009007320 A MX 2009007320A
Authority
MX
Mexico
Prior art keywords
antibodies
human cytomegalovirus
neutralising antibodies
well
epitopes
Prior art date
Application number
MX2009007320A
Other languages
English (en)
Spanish (es)
Inventor
Antonio Lanzavecchia
Annalisa Macagno
Original Assignee
Humabs Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37801734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009007320(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Humabs Llc filed Critical Humabs Llc
Publication of MX2009007320A publication Critical patent/MX2009007320A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2009007320A 2007-01-04 2008-01-03 Anticuerpos neutralizantes del citomegalovirus humano y su uso. MX2009007320A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0700133.2A GB0700133D0 (en) 2007-01-04 2007-01-04 Human cytomegalovirus neutralising antibodies and use thereof
PCT/IB2008/001111 WO2008084410A2 (en) 2007-01-04 2008-01-03 Human cytomegalovirus neutralising antibodies and use thereof

Publications (1)

Publication Number Publication Date
MX2009007320A true MX2009007320A (es) 2010-02-22

Family

ID=37801734

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007320A MX2009007320A (es) 2007-01-04 2008-01-03 Anticuerpos neutralizantes del citomegalovirus humano y su uso.

Country Status (31)

Country Link
US (4) US7955599B2 (enExample)
EP (3) EP2860189A3 (enExample)
JP (2) JP5710123B2 (enExample)
KR (2) KR101541927B1 (enExample)
CN (1) CN101657467B (enExample)
AU (1) AU2008204258B2 (enExample)
BR (1) BRPI0806185A2 (enExample)
CA (1) CA2673755C (enExample)
CO (1) CO6220862A2 (enExample)
CR (1) CR10961A (enExample)
CY (1) CY1114271T1 (enExample)
DK (1) DK2118140T3 (enExample)
EC (1) ECSP099547A (enExample)
ES (2) ES2426987T3 (enExample)
GB (1) GB0700133D0 (enExample)
GT (1) GT200900188A (enExample)
HR (1) HRP20130877T1 (enExample)
IL (1) IL199585A (enExample)
MA (1) MA31225B1 (enExample)
MX (1) MX2009007320A (enExample)
MY (2) MY161200A (enExample)
NZ (1) NZ578844A (enExample)
PL (1) PL2118140T3 (enExample)
PT (2) PT2118140E (enExample)
RU (1) RU2469045C2 (enExample)
SG (3) SG177943A1 (enExample)
SI (1) SI2118140T1 (enExample)
TN (1) TN2009000285A1 (enExample)
UA (1) UA100682C2 (enExample)
WO (1) WO2008084410A2 (enExample)
ZA (1) ZA200905408B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5822433B2 (ja) * 2006-06-07 2015-11-24 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
WO2009021150A2 (en) 2007-08-08 2009-02-12 California Pacific Medical Center Platelet derived growth factor receptor supports cytomegalovirus infectivity
CN102203133B (zh) 2008-07-16 2015-01-07 生物医学研究学会 人巨细胞病毒中和抗体及其应用
AU2012203417B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
WO2010007463A1 (en) * 2008-07-16 2010-01-21 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
NZ590890A (en) * 2008-07-25 2013-05-31 Inst Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
HRP20150623T1 (hr) 2009-04-01 2015-07-03 Evec Incorporated Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen
NZ600974A (en) * 2009-12-23 2014-08-29 4Antibody Ag Binding members for human cytomegalovirus
RU2613421C2 (ru) 2010-06-16 2017-03-16 ТРЕЛЛИС БАЙОСАЙЕНС, ЭлЭлСи Высокоаффинные антитела человека к белку gb цитомегаловирусу (cmv) человека
CA2841551C (en) 2011-07-18 2020-07-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US9139659B2 (en) 2012-03-28 2015-09-22 Genentech, Inc. Idiotypic antibodies and uses thereof
WO2014099908A1 (en) * 2012-12-17 2014-06-26 Genentech, Inc. Methods for inhibiting viral infection in transplant patients
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
CN106573154B (zh) 2014-07-15 2021-06-15 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
US20160069643A1 (en) * 2014-09-06 2016-03-10 Philip Lyren Weapon Targeting System
DK3303384T3 (da) 2015-06-01 2021-10-18 Medimmune Llc Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf
KR20180101483A (ko) 2016-01-08 2018-09-12 에임 쎄라퓨틱스 비.브이. 치료적 항-ｃｄ９ 항체
KR20250130692A (ko) 2016-01-13 2025-09-02 메디뮨 엘엘씨 인플루엔자 a의 치료 방법
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2017184562A1 (en) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
EP3749690A1 (en) * 2018-02-05 2020-12-16 Stichting VU Inverse agonistic anti-us28 antibodies
CN109580944A (zh) * 2018-12-07 2019-04-05 潍坊医学院 一种人巨细胞病毒检测试纸及其制造方法
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN109738631A (zh) * 2019-01-21 2019-05-10 潍坊医学院 一种人巨细胞病毒IgM抗体检测试纸的制备方法
CN118465272B (zh) * 2019-12-04 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
CN118772267B (zh) * 2022-10-21 2025-05-13 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1061943A (en) 1964-09-10 1967-03-15 Carter S Ink Co Marking composition
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4294817A (en) 1977-11-25 1981-10-13 International Diagnostic Technology, Inc. Method of fluoro immunoassay
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4313927A (en) 1979-10-19 1982-02-02 Ames-Yissum Ltd. Immunoassay method for detecting viral antibodies in whole blood samples
US4334016A (en) 1980-06-19 1982-06-08 The Wistar Institute Of Anatomy And Biology Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
FR2543570B1 (fr) 1983-03-31 1985-08-09 Pasteur Institut Anticorps monoclonaux anticytomegalovirus humains, hybridomes secreteurs de ces anticorps et polypeptides porteurs d'un determinant antigenique sequentiel de cytomegalovirus humains
US4617379A (en) 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
GB8404368D0 (en) 1984-02-20 1984-03-28 Cogent Ltd Monoclonal antibodies to human cytomegalovirus
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
FR2563630B1 (fr) 1984-04-27 1988-02-19 Pasteur Institut Anticorps monoclonaux anticytomegalovirus et procedes pour le diagnostic in vitro des infections par les cytomegalovirus humains et d'une proteine-kinase inductible par les cytomegalovirus et susceptible d'etre reconnue par les susdits anticorps monoclonaux
US4783399A (en) 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
US4743562A (en) 1984-08-21 1988-05-10 The Board Of Trustees Of The Leland Stanford Junior University Purified human cytomegalovirus protein
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4950595A (en) 1984-09-28 1990-08-21 Teijin Limited Mouse-human hybridoma which produces antivirus-human antibody, process for preparation thereof, and antivirus-human monoclonal antibody
US4808518A (en) 1985-02-11 1989-02-28 University Of Tennessee Research Corporation Recovery of cytomegalovirus antigen and use thereof in an assay
US4804627A (en) 1985-05-09 1989-02-14 Sloan-Kettering Institute For Cancer Research Method for cloning lymphoblastoid cells
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
ATE110084T1 (de) * 1985-12-06 1994-09-15 Teijin Ltd Anticytomegaloviraler menschlicher monoklonaler antikörper und dessen herstellung.
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5153311A (en) 1986-11-24 1992-10-06 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus gCII
US5126130A (en) 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
LU86752A1 (fr) 1987-01-30 1988-08-23 Univ Bruxelles Procede de production d'anticorps monoclonaux humains(igg)anticytomegalovirus et anticorps monoclonaux ainsi obtenus
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5180813A (en) 1989-03-24 1993-01-19 University Of Iowa Research Foundation Early envelope glycoprotein of human cytomegalovirus (hmcv) and monoclonal antibodies to the glycoproteins
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
WO1991004277A1 (en) 1989-09-14 1991-04-04 Children's Biomedical Research Institute Monoclonal antibodies specific to cytomegalovirus glycoprotein
WO1991005876A1 (en) 1989-10-20 1991-05-02 Children's Biomedical Research Institute Human cytomegalovirus-specific monoclonal antibody cocktail
GB9008223D0 (en) 1990-04-11 1990-06-13 Royal Free Hosp School Med Improvements relating to the detection of viruses
DE4035174A1 (de) 1990-11-06 1992-05-07 Biotest Ag Verfahren zur bestimmung von proteinen in koerperfluessigkeiten und mittel zur durchfuehrung des verfahrens
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
JPH053794A (ja) * 1991-06-26 1993-01-14 Green Cross Corp:The 抗サイトメガロウイルスヒトモノクローナル抗体およびその産生細胞
DE4128684A1 (de) 1991-08-29 1993-03-04 Behringwerke Ag Hcmv-spezifische peptide, mittel dazu und ihre verwendung
ATE173543T1 (de) 1992-04-10 1998-12-15 Thomas Totterman Verfahren zum nachweis einer cmv-infektion
SE9201281L (sv) 1992-04-23 1993-10-24 Bioinvent Int Ab Nya humana monoklonala antikroppar och förfarande för framställning därav
JPH05260961A (ja) * 1992-05-21 1993-10-12 Teijin Ltd サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
DE69418307T2 (de) 1993-01-21 1999-11-04 Erna Moeller Verhütung und behandlung von zytomegalovirus mittels aminopeptidase
US5750106A (en) 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
JPH08506325A (ja) 1993-01-28 1996-07-09 サンド ファーマスーティカル コーポレーション サイトメガロウイルスに対するヒトモノクローナル抗体
WO1994025490A1 (en) 1993-04-30 1994-11-10 The Scripps Research Institute Human monoclonal antibodies to human cytomegalovirus, and methods therefor
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
EP0702083A3 (de) 1994-07-26 1997-01-15 Biotest Ag Polypeptide und Fusionsproteine bestehend aus dem UL 57 Leserahmen bzw. dem C-terminalen Bereich des Tegumentproteins pp150 aus HCMV, entsprechende Oligonucleotide und Nachweis reagentien
US5783383A (en) 1995-05-23 1998-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of detecting cytomegalovirus (CMV)
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5800981A (en) 1996-02-22 1998-09-01 University Of Limburg Human cytomegalovirus antigen and its use
WO1998002746A1 (en) 1996-07-12 1998-01-22 Akzo Nobel N.V. Peptide reagent for the detection of human cytomegalovirus (cmv)
EP0964686A4 (en) 1996-08-14 2000-10-18 Wistar Inst METHODS AND COMPOSITIONS FOR PREVENTING OR INHIBITING THE DEVELOPMENT OF ATHEROSCLEROTIC DAMAGE
EP1003841A4 (en) 1997-01-30 2002-04-17 Cedars Sinai Medical Center CREATION OF A HSV-8 + LYMPHOMATORY CELL LINE, PRODUCT VIRUS, ANTIBODIES, DIAGNOSTIC METHOD AND KIT FOR DETECTING HSV-8 INFECTION
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
WO1998057993A1 (en) 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
JP2001512662A (ja) 1997-07-18 2001-08-28 コノート ラボラトリーズ リミテッド 呼吸器合胞体ウイルスのｇタンパク質をコードする核酸ワクチン
CA2309826A1 (en) 1997-11-14 1999-05-27 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
DE19756214C1 (de) 1997-12-17 1999-02-25 Biotest Ag Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie
ES2186340T3 (es) 1998-03-12 2003-05-01 Genentech Inc Utilizacion de polipeptidos fgf-5 para la prevencion de la muerte de neuronas retinales y para el tratamiento de enfermedades oculares.
AU5503899A (en) 1998-06-29 2000-01-17 Wolfgang Bergter Antiviral and antiretroviral radioimmunomedicaments based on alpha-emitters and beta-emitters
RU2133472C1 (ru) 1998-09-16 1999-07-20 Унитарное государственное Московское предприятие по производству бактерийных препаратов Способ диагностики активной стадии цитомегаловирусной инфекции человека
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
ITMI20012160A1 (it) 2001-10-18 2003-04-18 Edoardo Marchisio Sistema immunoenzimatico per la caratterizzazione antigenica dell'infezione attiva da cytomegalovirus e cmv confirmation test
US6828113B2 (en) 2002-03-21 2004-12-07 Cornell Research Foundation, Inc. IgM antibodies to the 70 kDa heat shock protein as a marker for cytomegalovirus infection
WO2003085121A2 (en) 2002-04-01 2003-10-16 Agensys, Inc. Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer
RU2239453C2 (ru) * 2002-12-03 2004-11-10 Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" Препарат иммуноглобулина человека против цитомегаловируса и способ его получения
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2004076645A2 (en) 2003-02-27 2004-09-10 University Of Massachusetts Compositions and methods for cytomegalovirus treatment
WO2004078926A2 (en) 2003-02-28 2004-09-16 Board Of Trustees Operating Michigan State University Immunologigal markers
EP2662390B1 (en) 2004-06-21 2017-08-02 E. R. Squibb & Sons, L.L.C. Interferon alpha receptor 1 antibodies and their uses
BE1016287A6 (nl) 2004-07-14 2006-07-04 Picanol Nv Gaapvormingsonderdeel voor een weefmachine en weefmachine.
WO2006056027A1 (en) 2004-11-29 2006-06-01 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
ATE503770T1 (de) 2005-03-14 2011-04-15 Us Gov Health & Human Serv Humane monoklonale antikörper gegen hendra- und nipah-viren
BRPI0619908A2 (pt) 2005-12-16 2011-10-25 Ribovax Biotechnologies Sa método para imortalização de uma população de células, população de células, população de células oligoclonal ou monoclonal, cultura celular, sobrenadante de uma cultura celular, biclioteca de dnas, uso de uma população de células, cultura celular, sobrenadante ou biblioteca de dnas, kit para identificar e produzir um anticorpo monoclonal, método para produzir uma cultura celular, e método para produzir um anticorpo monoclonal
WO2007094423A1 (ja) 2006-02-15 2007-08-23 Evec Incorporated ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
BRPI0712716A2 (pt) 2006-05-19 2012-05-22 Teva Pharma proteìna de fusão, composição, construção de ácido nucleico, vetor, célula transformada, preparação isolada de corpos de inclusão bacterialmente expressados, processo para produzir uma proteìna de fusão, e, métodos para matar seletivamente uma célula de tumor e para tratar uma célula de tumor que expressa mesotelina em sua superfìcie
JP5822433B2 (ja) 2006-06-07 2015-11-24 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ ワクチン中に薬剤標的として用いるサイトメガロウイルス表面タンパク質複合体
DK2126049T3 (da) 2006-12-15 2011-07-18 Ribovax Biotechnologies Sa Antistoffer mod humant cytomegalovirus (hCMV)
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
WO2008120203A2 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
US20080248042A1 (en) 2007-04-05 2008-10-09 Irccs Centro Di Riferimento Oncologico Di Aviano, Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc
EP2190876A1 (en) 2007-08-22 2010-06-02 Ribovax Biotechnologies SA Antibodies against human cytomegalovirus (hcmv)
US7763261B2 (en) 2007-12-19 2010-07-27 Dcb-Usa Llc Anti-human cytomegalovirus antibodies
WO2010007463A1 (en) 2008-07-16 2010-01-21 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
CN102203133B (zh) 2008-07-16 2015-01-07 生物医学研究学会 人巨细胞病毒中和抗体及其应用

Also Published As

Publication number Publication date
EP2487187B1 (en) 2014-10-22
GT200900188A (es) 2011-11-29
CY1114271T1 (el) 2016-08-31
MY161200A (en) 2017-04-14
CA2673755A1 (en) 2008-07-17
CO6220862A2 (es) 2010-11-19
SG191635A1 (en) 2013-07-31
US9149524B2 (en) 2015-10-06
CR10961A (es) 2009-11-20
AU2008204258B2 (en) 2012-09-06
KR20140101884A (ko) 2014-08-20
US8309089B2 (en) 2012-11-13
BRPI0806185A2 (pt) 2011-08-30
EP2118140B1 (en) 2013-06-19
HK1174344A1 (en) 2013-06-07
US7955599B2 (en) 2011-06-07
JP5710123B2 (ja) 2015-04-30
EP2860189A3 (en) 2015-07-29
JP2014141501A (ja) 2014-08-07
KR101541927B1 (ko) 2015-08-05
PL2118140T3 (pl) 2013-11-29
IL199585A (en) 2014-07-31
EP2118140A2 (en) 2009-11-18
ECSP099547A (es) 2009-11-30
RU2469045C2 (ru) 2012-12-10
US20120076802A1 (en) 2012-03-29
RU2009129403A (ru) 2011-02-10
US20130101604A1 (en) 2013-04-25
HK1139158A1 (en) 2010-09-10
SI2118140T1 (sl) 2013-10-30
US20140056914A1 (en) 2014-02-27
US8545848B2 (en) 2013-10-01
MA31225B1 (fr) 2010-03-01
US20080213265A1 (en) 2008-09-04
HRP20130877T1 (hr) 2013-10-25
MY150709A (en) 2014-02-28
AU2008204258A1 (en) 2008-07-17
SG192399A1 (en) 2013-08-30
EP2487187A2 (en) 2012-08-15
ZA200905408B (en) 2010-05-26
WO2008084410A3 (en) 2008-12-24
TN2009000285A1 (en) 2010-12-31
KR20090127256A (ko) 2009-12-10
ES2526907T3 (es) 2015-01-16
PT2118140E (pt) 2013-08-29
WO2008084410A2 (en) 2008-07-17
CA2673755C (en) 2016-04-05
CN101657467B (zh) 2013-11-06
CN101657467A (zh) 2010-02-24
ES2426987T3 (es) 2013-10-28
PT2487187E (pt) 2015-02-05
GB0700133D0 (en) 2007-02-14
NZ578844A (en) 2012-08-31
JP2010516229A (ja) 2010-05-20
EP2487187A3 (en) 2012-11-21
DK2118140T3 (da) 2013-07-01
UA100682C2 (ru) 2013-01-25
SG177943A1 (en) 2012-02-28
EP2860189A2 (en) 2015-04-15
KR101659306B1 (ko) 2016-09-23

Similar Documents

Publication Publication Date Title
TN2009000285A1 (en) Human cytomegalovirus neutralising antibodies and use thereof
TN2010000616A1 (en) Human cytomegalovirus neutralising antibodies and use thereof
PH12015500782A1 (en) Human cytomegalovirus neutralizing antibodies and use thereof
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
MX339083B (es) Proteinas de enlace a cd127.
MY156286A (en) Human il-23 antigen binding proteins
MX2012011768A (es) Anticuerpos que se unen a cd27 humano y uso de los mismos.
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
PH12017501732A1 (en) Therapeutic antibodies and their uses
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
WO2011062997A3 (en) Human monoclonal antibodies to human nucleolin
PH12012501793B1 (en) Monoclonal antibodies against c-met
SG178976A1 (en) High affinity human antibodies to human protease-activated receptor-2
MX2020012426A (es) Anticuerpos anti-cd38.
MX2010005022A (es) Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
MY156458A (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
WO2011092593A3 (en) Hiv-1 neutralizing antibodies and uses thereof
MX2010000979A (es) Metodos y composiciones para tratar enfermedad autoinmune.
IN2014MN02231A (enExample)
MY170404A (en) Antigen binding proteins
HK1156052A (en) Human cytomegalovirus neutralising antibodies and use thereof
AR121799A2 (es) Proteínas de unión a antígenos de il-23 humana
TN2010000621A1 (en) Human cytomegalovirus neutralizing antibodies and use thereof
TN2010000374A1 (en) Antibodies directed to angiopoietin -1 and angiopoietin-2 and use thereof
MX360580B (es) Autoanticuerpos humanos anti-alfa-sinucleina.

Legal Events

Date Code Title Description
HH Correction or change in general
GB Transfer or rights

Owner name: INSTITUTE FOR RESEARCH IN BIOMEDICINE

FG Grant or registration